|
12 May 2022 |
Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
|
|
11 May 2022 |
Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers
|
|
11 May 2022 |
Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans
|
|
11 May 2022 |
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
|
|
11 May 2022 |
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
|
|
11 May 2022 |
Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
|
|
11 May 2022 |
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
|
|
10 May 2022 |
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
|
|
10 May 2022 |
Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial
|
|
10 May 2022 |
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
|
|
10 May 2022 |
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
|
|
10 May 2022 |
Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors
|
|
10 May 2022 |
Pfizer to Acquire Biohaven Pharmaceuticals
|
|
10 May 2022 |
Eisai completes rolling submission to the U.S. FDA for biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway
|
|
10 May 2022 |
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
|
|
09 May 2022 |
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
|
|
09 May 2022 |
Ichnos Sciences announces selection of trispecific antibody ISB 2001 as next clinical candidate for relapsed/refractory multiple myeloma
|
|
09 May 2022 |
Elpiscience Announces FDA IND Clearance of ES014, a First-in-Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
|
|
09 May 2022 |
Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors
|
|
09 May 2022 |
Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression
|
